Navigation Links
Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

versions of Allegra(R) and Neurontin(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Jeffrey Cohen, M.D., is a member of Teva's Scientific Advisory Board.

Contact

Teva Pharmaceutical Industries Ltd.
Dan Suesskind, 011-972-2-589-2840
Chief Financial Officer
or
Teva North America
George Barrett, 215-591-3030
President and CEO
or
Teva Investor Relations
Liraz Kalif / Kevin Mannix
011-972-3-926-7281 / 215-591-8912


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:9/19/2014)... LYNBROOK, N.Y. , Sept. 19, 2014  BioSpecifics Technologies ... first in class collagenase-based products marketed as XIAFLEX ® ... announced today that BioSpecifics, President, Tom Wegman , will ... BioCentury NewsMakers in the Biotech Industry Conference. ... at 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... NEW YORK, Jan. 10, 2012  ( http://www.myprgenie.com/  ) ... Americans 10 years ago and ask them where they found ... their current healthcare provider in their insurance plan directory or ... that is not the case.  Eighty percent of all U.S. ...
... uVera Diagnostics has introduced the CR3 Keyless Split Sample Cup ... cup provides several state-of-the-art features not available together in any ... to the drug testing industry," said Rick Nee, president of ... of use for both genders. The unique patented device is ...
Cached Medicine Technology:Castle Connolly Makes Finding the Best Healthcare from Top Doctors Even Easier 2uVera Diagnostics Offers New Drug Screening Product 2
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 In partnership ... has been an active part of the project’s social media ... movement, which aims to re-define the perception of beauty as ... Project began as an idea by Shelly Baer and Vanessa ... disabled women as sexy and beautiful. Ginny Dixon, Wendy Crawford, ...
(Date:9/19/2014)... Researchers at Jacksonville,s campus of Mayo Clinic have discovered ... contributes to both overproduction of toxic protein in the ... as loss of communication between neurons both significant ... in the online issue of Neuron ... with drugs "may rejuvenate or rescue this pathway," says ...
(Date:9/19/2014)... states are passing legislation permitting or requiring schools to ... having a severe allergic reaction. Epinephrine auto-injectors are ... can lead to throat swelling, breathing difficulties, a steep ... In people with severe allergies to certain foods, such ... drugs, anaphylaxis can occur within moments of exposure to ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... 2014 Capital Region Periodontics and ... excited to announce the latest addition to their ... and those needing dental implants. Often referred to ... removes the fear factor normally associated with traditional ... and bleeding make, this procedure a very attractive ...
Breaking Medicine News(10 mins):Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3
... ... ... WASHINGTON , March 17 The following is a statement by ... , , ...
... , TAMPA, Fla. , March 17 ... features to enhance its acclaimed study program for the ... exams. Effective immediately, 30 animated muscle tutorials, 25 interactive study ... nationwide. These features, which include narration for auditory learners, further ...
... understanding of the Skp2 gene and its relation to cellular ... can suppress tumor development in common types of cancer, researchers ... and Memorial Sloan-Kettering Cancer Center report in the journal ... cycle regulation, cell proliferation, cell growth and the formation of ...
... potentially deadly infections long has focused on looking for ways ... University of Utah and Utah State University shows that modulating ... save more lives. In a study published March ... U of U cardiologist Dean Y. Li, M.D., Ph.D., professor ...
... an indicator of more serious disease, study finds , ... bowel syndrome (IBS) aren,t at increased risk for polyps, ... disease and, in most cases, don,t require a colonoscopy, ... 10 percent to 20 percent of Americans, include recurrent ...
... WHEATON, Ill. , March 17 ... Organizational Planning, John Brady , DHA, has been ... with Disabilities Task Force. The Task Force is responsible ... changes, recommendations, and innovations may be needed to enhance ...
Cached Medicine News:Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 2Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 2Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 5Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 6Health News:Disabling Skp2 gene helps shut down cancer growth 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Colonoscopy Not Needed for Most With Irritable Bowel Syndrome 2Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: